CGTLive®’s Weekly Rewind – June 28, 2024

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Vertex’s Diabetes Cell Therapy on Track to Meet Endpoint of Eliminating Severe Hypoglycemic Events

All 3 participants who have follow-up of at least 1 year have met the endpoint so far.

2. Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development

The head of research at Mass General Brigham’s Cell and Gene Therapy Institute discussed work the center is engaged in with cell and gene therapy.

3. Kyverna’s CAR-T KYV-101 Shows Some Durable Responses in Autoimmune Disease, With One Relapse Reported

One patient is considered disease-free at 1 year posttreatment, but another patient’s disease relapsed at 5 months.

4. Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

5. enGene Tackles Nonmuscle-Invasive Bladder Cancer With Expansive Phase 1/2 LEGEND Trial for Gene Therapy EG-70

With the company having recently announced that it intends to expand the clinical trial with a new cohort, CGTLive® has decided to take a closer look at this ongoing study.